NEW YORK – T-Cure Bioscience and Immunotech Biopharm on Wednesday said they have entered into a licensing agreement concerning the development and commercialization of T-Cure's autologous kidney cancer T-cell receptor therapy, 800TCR, in China.
The companies did not disclose the financial details of their deal. However, Beijing-based Immunotech will make an upfront payment to T-Cure in California for the rights to develop and commercialize 800TCR in China. The firm will also make milestone payments to T-Cure, as well as tiered royalty payments on potential future sales.